JP7322036B2 - Ccr6またはcxcr2のアンタゴニストを用いて汎発性膿疱性乾癬を治療する方法 - Google Patents

Ccr6またはcxcr2のアンタゴニストを用いて汎発性膿疱性乾癬を治療する方法 Download PDF

Info

Publication number
JP7322036B2
JP7322036B2 JP2020537663A JP2020537663A JP7322036B2 JP 7322036 B2 JP7322036 B2 JP 7322036B2 JP 2020537663 A JP2020537663 A JP 2020537663A JP 2020537663 A JP2020537663 A JP 2020537663A JP 7322036 B2 JP7322036 B2 JP 7322036B2
Authority
JP
Japan
Prior art keywords
ccr6
cxcr2
compound
cells
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020537663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510160A5 (cg-RX-API-DMAC7.html
JP2021510160A (ja
Inventor
ジェイ.キャンベル ジェイムズ
エブスワース カレン
クラシンスキー アントーニ
レディー マリ ベンカット
マクマホン ジェフリー
シン ラジンダー
チュイ ヤン
チャオ ユイ
チャン ペングリー
Original Assignee
ケモセントリックス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス,インコーポレイティド filed Critical ケモセントリックス,インコーポレイティド
Publication of JP2021510160A publication Critical patent/JP2021510160A/ja
Publication of JP2021510160A5 publication Critical patent/JP2021510160A5/ja
Application granted granted Critical
Publication of JP7322036B2 publication Critical patent/JP7322036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020537663A 2018-01-08 2019-01-07 Ccr6またはcxcr2のアンタゴニストを用いて汎発性膿疱性乾癬を治療する方法 Active JP7322036B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862614927P 2018-01-08 2018-01-08
US62/614,927 2018-01-08
US201862715503P 2018-08-07 2018-08-07
US62/715,503 2018-08-07
PCT/US2019/012519 WO2019136370A2 (en) 2018-01-08 2019-01-07 Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2

Publications (3)

Publication Number Publication Date
JP2021510160A JP2021510160A (ja) 2021-04-15
JP2021510160A5 JP2021510160A5 (cg-RX-API-DMAC7.html) 2022-01-17
JP7322036B2 true JP7322036B2 (ja) 2023-08-07

Family

ID=67140280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020537663A Active JP7322036B2 (ja) 2018-01-08 2019-01-07 Ccr6またはcxcr2のアンタゴニストを用いて汎発性膿疱性乾癬を治療する方法

Country Status (10)

Country Link
US (2) US11207294B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737366B1 (cg-RX-API-DMAC7.html)
JP (1) JP7322036B2 (cg-RX-API-DMAC7.html)
CN (1) CN111867579B (cg-RX-API-DMAC7.html)
AU (1) AU2019205786B2 (cg-RX-API-DMAC7.html)
ES (1) ES3067325T3 (cg-RX-API-DMAC7.html)
IL (1) IL275839B2 (cg-RX-API-DMAC7.html)
MA (1) MA50424A (cg-RX-API-DMAC7.html)
TW (1) TWI821235B (cg-RX-API-DMAC7.html)
WO (1) WO2019136370A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
ES3067325T3 (en) 2018-01-08 2026-05-21 Chemocentryx Inc Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
CN117018202A (zh) * 2019-07-08 2023-11-10 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
TWI904157B (zh) 2020-04-30 2025-11-11 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
JP2024539987A (ja) 2021-10-26 2024-10-31 イドルシア・ファーマシューティカルズ・リミテッド Ccr6受容体調節剤
ES3073199T3 (en) 2021-10-28 2026-07-09 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170430A1 (ja) 2014-05-08 2015-11-12 学校法人慶應義塾 大動脈解離後の炎症性障害抑制剤
WO2017087607A1 (en) 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulators of chemokine receptors

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AR033803A1 (es) 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
WO2001092202A1 (en) 2000-05-30 2001-12-06 Smithkline Beecham Corporation Il-8 receptor antagonists
DE60230722D1 (de) 2001-01-16 2009-02-26 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
EP1355875A1 (en) 2001-02-02 2003-10-29 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR20100008794A (ko) 2001-04-16 2010-01-26 쉐링 코포레이션 Cxc-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
NZ535314A (en) 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
DE602004025458D1 (de) 2003-04-18 2010-03-25 Schering Corp SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID
CN1914187B (zh) 2004-01-30 2012-01-25 先灵公司 Cxc趋化因子受体配位体的结晶多晶型物
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
JP2009542700A (ja) 2006-07-07 2009-12-03 シェーリング コーポレイション Cxcケモカイン受容体リガンドとしての3,4−ジ置換シクロブテン−1,2−ジオン
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
MX2009013276A (es) 2007-06-06 2010-01-25 Novartis Ag Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
EP2178826B1 (en) 2007-07-03 2017-05-17 Merck Sharp & Dohme Corp. Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
US20100249439A1 (en) 2007-07-05 2010-09-30 Vincenzo Liotta Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
MX2010014310A (es) 2008-06-24 2011-02-15 Topotarget As Derivados de acido escuarico como inhibidores de la nicotinamida.
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2350067A2 (en) 2008-10-16 2011-08-03 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
WO2013030803A1 (en) 2011-09-02 2013-03-07 Novartis Ag Choline salt of an anti - inflammatory substituted cyclobutenedione compound
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
SI2780373T1 (sl) * 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
EP3220951A1 (en) 2014-11-17 2017-09-27 MedImmune Limited Therapeutic combinations and methods for treating neoplasia
TWI724056B (zh) * 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
ES3067325T3 (en) 2018-01-08 2026-05-21 Chemocentryx Inc Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170430A1 (ja) 2014-05-08 2015-11-12 学校法人慶應義塾 大動脈解離後の炎症性障害抑制剤
WO2017087607A1 (en) 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulators of chemokine receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
医学のあゆみ,2012年,Vol.242, No.10, pp.799-804

Also Published As

Publication number Publication date
US11684606B2 (en) 2023-06-27
TWI821235B (zh) 2023-11-11
US20190209527A1 (en) 2019-07-11
AU2019205786A1 (en) 2020-08-06
CA3087701A1 (en) 2019-07-11
EP3737366A2 (en) 2020-11-18
US11207294B2 (en) 2021-12-28
WO2019136370A3 (en) 2020-04-16
US20220280481A1 (en) 2022-09-08
ES3067325T3 (en) 2026-05-21
WO2019136370A2 (en) 2019-07-11
CN111867579B (zh) 2023-11-24
MA50424A (fr) 2020-08-26
CN111867579A (zh) 2020-10-30
IL275839B2 (en) 2024-02-01
JP2021510160A (ja) 2021-04-15
IL275839B1 (en) 2023-10-01
TW201936600A (zh) 2019-09-16
IL275839A (en) 2020-08-31
EP3737366A4 (en) 2022-07-27
AU2019205786B2 (en) 2023-12-14
EP3737366B1 (en) 2026-02-25
EP3737366C0 (en) 2026-02-25

Similar Documents

Publication Publication Date Title
US11684606B2 (en) Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
JP7611189B2 (ja) Pd-1阻害剤又はpd-l1阻害剤と組み合わせてccr1アンタゴニストを投与することによる腫瘍負荷の低減
JP7788814B2 (ja) C3腎症を処置する方法
EP2167038B1 (en) Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
Nitahara-Kasahara et al. Inflammatory predisposition predicts disease phenotypes in muscular dystrophy
US20240390378A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
O’Reilly Emerging therapeutic targets in systemic sclerosis
JP2023506118A (ja) 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
CA3087701C (en) Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
JPWO2020004404A1 (ja) IL−1β阻害薬
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
HK40004572B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230726

R150 Certificate of patent or registration of utility model

Ref document number: 7322036

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150